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Gliomas are the second most common primary brain tumors,
with an incidence of 4–5/100 000 individuals. Gliomas are the
second leading cause of cancer mortality in adults under the
age of 35, the fourth leading cause in those under the age of
54, and result in death in approximately 13 770 individuals per
year in the United States.1 Median survival of glioblastoma, the
most aggressive variant, is 16 months in patients treated with
maximum safe resection, radiotherapy, and concurrent and ad-
juvant temozolomide in clinical trial populations.2–4
MRI is the mainstay of imaging of gliomas to monitor both
treatment and response. T1-weighted MRI without and with
contrast medium, T2-weighted as well as fluid-attenuated in-
version recovery (FLAIR) MRI sequences are used for anatomic
imaging. However, many brain tumors (particularly World
Health Organization [WHO] grade II and a significant number
of WHO grade III gliomas) do not enhance with contrast-agent
administration, reducing the ability of contrast imaging to ac-
curately quantify tumor burden. The challenge to accurately
determine brain tumor response by MRI both in daily practice
and in clinical trials has led to the introduction of updated
guidelines by the Response Assessment in Neuro-Oncology
(RANO) working group.5
Functional molecular imaging such as positron emission to-
mography (PET) uses various tracers to visualize biological pro-
cesses such as cell proliferation, membrane biosynthesis,
glucose consumption, and uptake of amino acid analogs.6
Hence, PET provides additional insight beyond MRI into the biol-
ogy and treatment response of gliomas which may be used for
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noninvasive grading, differential diagnosis, delineation of
tumor extent, surgical and radiotherapy treatment planning,
posttreatment surveillance, and prognostication.
Analogous to the RANOeffort regardingMRI use in gliomas, an
initiative was undertaken by a group of clinicians and nuclear
medicine physicians to similarly define standards of molecular
imaging for gliomas using PET with respect to interpretation
and validation as well as to define its role in clinical practice.
In this paper, evidence-based recommendations are proposed
for the use of PET imaging in the clinical management of glio-
ma patients. Accordingly, the review discusses tracers which
image glucose metabolism—18F-2-fluoro-2-deoxy-D-glucose
(18F-FDG)—and amino acid transport ([11C-methyl]-methionine
(11C-MET), O-(2-[18F]-fluoroethyl)-L-tyrosine (18F-FET) and
3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-FDOPA)), since
these compounds have already entered clinical practice.
The current guidelines aim to serve medical professionals of
all disciplines involved in the diagnosis and care of patients with
gliomas. A separate procedural guideline focusing on the
standardization of technical aspects of PET imaging for glioma
will be the subject of another paper prepared by the EANM (Eu-
ropean Association of Nuclear Medicine)/EANO (European Asso-
ciation of Neuro-Oncology)/RANO groups.
Levels of Validation and Clinical Evidence
Search Strategy and Selection Criteria
The information retrieved from a PubMed search of the pub-
lished literature with the combination of the search terms “gli-
oma,” “glioblastoma,” “brain tumor,” “PET,” “FDG,” “FET,”
“MET,” and “DOPA” until September 2015 as well as from arti-
cles identified through searches of the authors’ own files
was evaluated by the working group with respect to the level
of evidence and the grade of validation of the PET studies
examined.
Any study that correlated the PET findings with histopathol-
ogy was considered to represent the highest degree of valida-
tion. Next, correlation with MRI (when applicable, according to
RANO criteria) and with the patient’s clinical course was used
for the second level of validation. Only papers constituting lev-
els 1–3 evidence according to the Oxford Centre for Evidence-
based Medicine (OCEBM Levels of EvidenceWorking Group: “The
Oxford 2011 Levels of Evidence”) were included.
General Recommendations
Recommendations for clinical use and diagnostic performance
of differing PET tracers compared with MRI are presented in
Tables 1 and 2 and in Fig. 1.
Specific Recommendations
Primary Diagnosis/Differential Diagnosis
18F-FDG PETmay provide useful information for distinguishing
WHO grade III/IV gliomas from other malignant brain tumors,
but its specificity is limited. Importantly, maximum standard-
ized uptake values (SUVmax) were significantly higher in primary
CNS lymphomas than in glioblastoma.7,8 However, corticoste-
roid medication may reduce uptake.
The differential diagnosis by 18F-FDG PET between WHO
grades III/IV gliomas and brain metastases is limited, since
considerable overlap of SUVmax exists between these tumor
types.7 18F-FDG PETalso has limited specificity for distinguishing
glioma from other nonneoplastic lesions, such as brain ab-
scesses, demyelinating tumefactive (“tumor-like”) lesions, fun-
gal infections, and neurosarcoidosis9 due to increased 18F-FDG
metabolism in inflammatory tissue.
Amino acid PET is useful for the noninvasive differentiation of
tumor and nontumoral processes, as tumors have significantly
higher uptake than nonneoplastic tissue.10,11 However, moder-
ately increased uptake can also be seen in acute inflammatory
lesions such as activemultiple sclerosis and brain abscesses.12,13
Conversely, lack of 18F-FET uptake does not exclude a glioma, as
approximately one-third of WHO grade II gliomas andmost dys-
embryoplastic neuroepithelial tumors (WHO grade I) are 18F-FET
negative.14 However, amongWHO grades III and IVgliomas, the
vast majority (.95%) show increased uptake,11,12,15 with a re-
sultant high sensitivity for the detection of these tumors. A re-
cent meta-analysis revealed that for brain tumor diagnosis,
18F-FET PETperformedmuch better than 18F-FDG PETand conse-
quently would be the preferred PET tracer when assessing pa-
tients with a newly diagnosed brain tumor.16 Furthermore,
numerous studies validated by histology have demonstrated
higher diagnostic accuracy of additional amino acid PET com-
pared with anatomic MRI alone for the differentiation of gliomas
from nonneoplastic lesions.11,12,17–19
† In cases of diagnostic uncertainty, amino acid PET improves
sensitivity, specificity, and accuracy and is markedly superior
to 18F-FDG PET in differentiating between glioma and non-
neoplastic tissue.
Tumor Grading
The value of 18F-FDG PET for grading of gliomas is hampered by
the poor tumor-to-background contrast due to physiologically
increased glucose uptake of cortical and subcortical (basal gan-
glia, thalamus) structures in brain and high variation of uptake
and overlap of uptake values between tumors of different WHO
grades, especially in oligodendroglial tumors.20,21 However,
WHO grades III and IV gliomas generally have higher 18F-FDG
values than WHO grade II gliomas, which often appear as a
hypometabolic lesion, particularly when compared with the up-
take in the cortex.16
Characteristically, amino acid uptake is higher in gliomas of
WHO grades III/IV compared with WHO grade II gliomas. How-
ever, uptake intensities may vary, and tumor-to-brain ratios
show a considerable overlap between different WHO grades as
well as histological subtypes.11,12,22–24 For 18F-FET, accuracy
for tumor grading can be markedly improved by evaluating dy-
namic (kinetic) PETdata, which typically show steadily increasing
time-activity curves in WHO grade II gliomas, as opposed to an
early activity peak around 10–20 min after injection, followed by
a decrease of 18F-FET uptake in WHO grades III/IV gliomas.22,25
This is particularly valuable in the clinical setting of patients with
MRI non-contrast-enhancing gliomas suspected of harboring a
WHO grade II glioma. In approximately 40% of such cases, an
anaplastic focus is demonstrated.14,26 In these patients, kinetic
analysis provides a higher sensitivity and specificity for the
detection of WHO grades III/IV gliomas (95%).14 This method
i i i glio s
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of kinetic analysis does not work for 11C-MET24; and for
18F-FDOPA, data are still controversial.27,28
† Although 18F-FDG and amino acid uptake are usually higher
in WHO grades III/IV gliomas than in WHO grade II gliomas,
tumor grading is limited due to significant overlap in uptake
values.
† Dynamic analysis of 18F-FET PET uptake further improves dif-
ferential diagnosis between WHO grade II and WHO grades
III/IV gliomas.
Delineation of Glioma Extent
Multiple histopathological and postmortem series demonstrate
the limitations of conventional MRI in defining the extent of gli-
oma.29,30 Moreover, the usefulness of 18F-FDG PET in tumor
delineation, given high uptake in normal brain cortex and low
uptake in WHO grade II gliomas, is particularly limited for cor-
tical or pericortical tumors, even when dual-timepoint images
are performed.31 In contrast, amino acid PET imaging more
accurately identifies infiltrating regions of tumor extending be-
yond the MRI contrast-enhancing lesion and often distinguish-
es among tumor, nontumoral edema, and normal brain.32 In
addition, amino acid PET provides functional and metabolic in-
formation about the tumor and may identify tumor regions
with different biological and clinical behavior. In both WHO
grade II and WHO grades III/IV gliomas, amino acid PET com-
plements conventional MRI by providing additional information
about tumor extent and biology.
WHO grades III/IV glioma
Both the uptake and image contrast between tumor and nor-
mal tissue of amino acid tracers such as 11C-MET and 18F-FET
Table 1. Diagnostic performance of different amino acid tracers compared with conventional and advanced MRI
Clinical Problem MET FET FDOPA
Differentiation of glioma from
nonneoplastic lesions
Numerous studies,19 higher
diagnostic accuracy than
MRI alone
Higher diagnostic accuracy than MRI
alone11,12,18
Not available for the initial
diagnosis
Glioma grading (including
detection of anaplastic foci)
Higher diagnostic accuracy
than MRI, but still limited
accuracy due to high overlap
between WHO grades19,96
Higher diagnostic accuracy than MRI, in
particular for dynamic PET14,26,93
High accuracy by combination of
dynamic FET-PET and diffusion MRI97
No studies available comparing
directly PETwith MRI; in the pure
PET studies, conflicting results
reporting high38,98 and low28,99
performance
Delineation of glioma extent Metabolically active tumor
larger than contrast
enhancement in LGG and
HGG at diagnosis and
recurrence100,101
Delineatesmetabolically active
tumor in non-enhancing
anaplastic glioma32,102
In newly diagnosed glioblastoma,
metabolically active tumor larger
than CE pre- and
postoperatively46,103
In WHO grades II/IV gliomas
metabolically active tumor larger
than rCBV104
In glioma, metabolically active
tumor larger than rCBV,105
ADC,106 and contrast
enhancement34,36
Differentiation of glioma
recurrence from
treatment-induced changes
(eg, pseudoprogression,
radionecrosis)
Higher diagnostic accuracy
than MRI66
Higher diagnostic accuracy than
MRI74,81,107
Higher diagnostic accuracy than
MRI17,37,79,108
Assessment of treatment
response (including
pseudoresponse)
Superior to MRI; metabolic
response to TMZ predictive
for survival70
Superior to MRI; metabolic responses to
TMZ,83 RT,69,71 and BEV76,78 occurred
earlier and/or were associated with
improved survival
Superior to MRI; metabolic
response to BEV77 occurred
earlier and was predictive of
improved survival
Assessment of prognosis in
gliomas
In contrast to pretreatment CE
volumes, metabolically
active tumor volumes are
prognostic in HGG86,95
Metabolically active tumor volume is
prognostic in WHO grade IV glioma.46
Higher prognostic value of time-activity
curves in dynamic PET than MRI
withinWHO grade II andWHO grades
III/IV glioma.15,91,92
FET uptake in combination with specific
MRI findings is prognostic94 for WHO
grade II glioma
Superior to MRI in WHO grade II
glioma; maximum uptake is an
independent predictor of
progression109
Abbreviations: LGG, low-grade glioma; HGG, high-grade glioma; CE, contrast enhancement; rCBV, relative cerebral blood volume; ADC, apparent
diffusion coefficient; TMZ, temozolomide; RT, radiotherapy; BEV, bevacizumab.
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Table 2. Overview of histologically validated amino acid PET studies in gliomas
Clinical Problem MET FET FDOPA
Differentiation of neoplastic from
nonneoplastic lesions
Stereotactic biopsy110
Hot-spot guided resection111
Stereotactic biopsy and hot-spot
guided resection11
n.a.
Differentiation betweenWHO grades II
and WHO grades III/IV glioma
In a subset of patients
stereotactic biopsy112
Stereotactic biopsy14,22,25 In a subset of patients
stereotactic biopsy and
hot-spot guided resection38
Delineation of glioma extent Stereotactic biopsy39,43,113,114
Hot-spot guided resection101,115
Stereotactic biopsy41,116
Stereotactic biopsy and hot-spot
guided resection117
In a subset of patients
hot-spot guided resection36
Differentiation of glioma recurrence
from treatment-induced changes
(eg, radionecrosis)
Stereotactic biopsy118 Stereotactic biopsy119
Stereotactic biopsy and hot-spot
guided resection81,120
In a subset of patients
stereotactic biopsy17,108
Detection of malignant tumor parts in
MRI findings suggestive for WHO
grade II glioma
Stereotactic biopsy and hot-spot
guided resection96
Stereotactic biopsy26
Stereotactic biopsy and hot-spot
guided resection93
n.a.
Assessment of prognosis in untreated
gliomas
Histological confirmation of
glioma only95 (local
comparison not necessary)
Histological confirmation of
glioma only15,91 (local
comparison not necessary)
Histological confirmation of
glioma only109 (local
comparison not necessary)
Abbreviation: n.a., not available.
Fig. 1. Overview of indications for amino acid PET.
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are similar.33 PET-based tumor volumes have been shown to
extend beyond the contrast-enhancing volume on convention-
al MRI by 2–3.5 cm for different tracers.34 –37 In addition,
amino acid PET identifies tumor extent within nonspecific re-
gions of T2/FLAIR signal abnormality.34,36
WHO grade II glioma
Most WHO grade II gliomas are nonenhancing with infiltrating
tumor borders that are difficult to delineate by conventional
MRI. Several studies have demonstrated the usefulness of
amino acid PET in defining tumor extent. This has been demon-
strated in histology-validated series for 11C-MET, 18F-FET, and
18F-FDOPA PET.17,38–41
† 18F-FDG is not suitable for glioma volume delineation.
† Delineation of tumor borders by amino acid PET is superior to
standard MRI both in contrast-enhancing as well as
non-contrast-enhancing gliomas.
Value for Treatment Planning: Biopsy and Resection
Implementation of PET into biopsy and resection planning is ad-
vantageous, as PET better delineates tumor extent compared
with standard MRI and additionally identifies intratumoral het-
erogeneity, including malignant foci in non-contrast-enhancing
gliomas.
Numerous studies have investigated the benefit of incorpo-
rating 18F-FDG or amino acid PET into biopsy target planning.
The identification of malignant foci (“hot spots”) in MRI hetero-
geneous gliomas is essential for biopsy planning to ensure that
the biologically most aggressive portion of the tumor, which
determines the patient’s prognosis as well as treatment, is
not undersampled.26,42 There are several reports that illustrate
the advantages of amino acid PET–based resection planning,
of considerable importance whenever functional, eloquent
areas may be involved,26,34,43 and which demonstrate a higher
probability of detecting more highly malignant areas within an
MRI heterogeneous glioma as well as decreased risk of incom-
plete resection.44,45,46
† Integration of amino acid PET into surgical planning allows
better delineation of the extent of resection beyond margins
visible with standard MRI. This is of considerable importance
whenever functional eloquent areas of brain are involved.
† For biopsy planning, amino acid PET is particularly helpful in
identifying malignant foci within non-contrast-enhancing
gliomas.
Value for Treatment Planning: Radiation
Beyond MRI-based morphologic gross tumor volume delinea-
tion, a biological tumor volume may be defined by radiotracer
uptake on amino acid PET that identifies tumor beyond the ex-
tent visible with standard MRI.47 In addition, the biologic and
metabolic information provided by PETmay identify subregions
of tumor at higher risk of recurrence, which can be included in
the radiation boost volume. The ability to better define tumor
extent and biology may be used to improve the therapeutic
ratio of radiation treatment. The current recommendations
focus on the role of PET for radiation planning of WHO grades
III/IV gliomas, as the role of PET imaging in irradiation of WHO
grade II gliomas is not well established.
Small, prospective studies systematically comparing contrast
MRI tumor volume (the “standard” radiation boost target) and
18F-FDG uptake abnormality generally demonstrate a smaller
region of 18F-FDG uptake contained within the MRI abnormality,
with only occasional extension outside of the MRI target.48,49 Al-
though small studies have demonstrated the feasibility of radia-
tion boost planning using 18F-FDG PET, its utility is limited by the
low contrast between tumor and normal cortex.48
Studies analyzing patterns of failure following conventional
chemoradiotherapy based on standard MRI-defined tumor vol-
umes suggest that amino acid PET–defined tumor volumes
may yield a more appropriate radiation target volume.50–52
In these small studies, a proportionate increase in marginal
or noncentral tumor recurrences were seen when regions of
11C-MET and 18F-FET abnormality were not adequately covered
by high-dose radiation. Prospective, single-arm studies evaluat-
ing the use of amino acid PET for radiation treatment planning
of recurrent WHO grades III/IV glioma suggest the feasibility of
this approach, and most studies suggest an improvement in
outcome compared with radiation planning based on conven-
tional MRI alone.53,54 However, the inclusion of amino acid
PET–based tumor volumes in standard-dose radiation therapy
and reirradiation protocols continue to demonstrate a predom-
inance of in-field tumor recurrences, highlighting the need for
more effective therapies.53–56
† Amino acid PET may improve the delineation of a biological
tumor volume beyond conventional MRI and identify aggres-
sive tumor subregions that may be targeted by radiation
therapy.
† While 18F-FDG PET is of limited utility in radiation treatment
planning of WHO grades III/IV gliomas, radiation planning
using amino acid PET appears feasible, with preliminary evi-
dence of potential benefit.
Follow-up: Treatment Response, Progression,
Pseudoprogression, and Radionecrosis
To date, standard, structural MRI is the most important diagnos-
tic tool for assessing treatment effects in patients with gliomas.4
The extent of contrast enhancement on MRI is usually consid-
ered an indicator of treatment response (eg, Macdonald criteria,
RANO criteria),5,57 although its reliability in distinguishing tumor
tissue from treatment effects, which can include blood–brain
barrier breakdown, is limited.58 For example, transient blood–
brain barrier alteration with contrast enhancement—such as
after radiotherapy with or without concomitant temozolomide—
can mimic tumor progression and is termed “pseudoprogres-
sion.”59,60 In addition, since the introduction of anti-angiogenic
agents such as bevacizumab, the phenomenon of pseudores-
ponse complicates the assessment of treatment response using
standard MRI alone.59,61
WHO grades III/IV glioma
Few 18F-FDG PET studies have measured the glucose metabolic
rate following either radiotherapy, chemotherapy, or both:
decrease of 18F-FDG uptake correlates with treatment
Albert et al.: Recommendations for PET imaging in gliomas
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Table 2. Overview of histologically validated amino acid PET studies in gliomas
Clinical Problem MET FET FDOPA
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Hot-spot guided resection111
Stereotactic biopsy and hot-spot
guided resection11
n.a.
Differentiation betweenWHO grades II
and WHO grades III/IV glioma
In a subset of patients
stereotactic biopsy112
Stereotactic biopsy14,22,25 In a subset of patients
stereotactic biopsy and
hot-spot guided resection38
Delineation of glioma extent Stereotactic biopsy39,43,113,114
Hot-spot guided resection101,115
Stereotactic biopsy41,116
Stereotactic biopsy and hot-spot
guided resection117
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hot-spot guided resection36
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from treatment-induced changes
(eg, radionecrosis)
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Stereotactic biopsy and hot-spot
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Detection of malignant tumor parts in
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grade II glioma
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guided resection96
Stereotactic biopsy26
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guided resection93
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comparison not necessary)
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Fig. 1. Overview of indications for amino acid PET.
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are similar.33 PET-based tumor volumes have been shown to
extend beyond the contrast-enhancing volume on convention-
al MRI by 2–3.5 cm for different tracers.34 –37 In addition,
amino acid PET identifies tumor extent within nonspecific re-
gions of T2/FLAIR signal abnormality.34,36
WHO grade II glioma
Most WHO grade II gliomas are nonenhancing with infiltrating
tumor borders that are difficult to delineate by conventional
MRI. Several studies have demonstrated the usefulness of
amino acid PET in defining tumor extent. This has been demon-
strated in histology-validated series for 11C-MET, 18F-FET, and
18F-FDOPA PET.17,38–41
† 18F-FDG is not suitable for glioma volume delineation.
† Delineation of tumor borders by amino acid PET is superior to
standard MRI both in contrast-enhancing as well as
non-contrast-enhancing gliomas.
Value for Treatment Planning: Biopsy and Resection
Implementation of PET into biopsy and resection planning is ad-
vantageous, as PET better delineates tumor extent compared
with standard MRI and additionally identifies intratumoral het-
erogeneity, including malignant foci in non-contrast-enhancing
gliomas.
Numerous studies have investigated the benefit of incorpo-
rating 18F-FDG or amino acid PET into biopsy target planning.
The identification of malignant foci (“hot spots”) in MRI hetero-
geneous gliomas is essential for biopsy planning to ensure that
the biologically most aggressive portion of the tumor, which
determines the patient’s prognosis as well as treatment, is
not undersampled.26,42 There are several reports that illustrate
the advantages of amino acid PET–based resection planning,
of considerable importance whenever functional, eloquent
areas may be involved,26,34,43 and which demonstrate a higher
probability of detecting more highly malignant areas within an
MRI heterogeneous glioma as well as decreased risk of incom-
plete resection.44,45,46
† Integration of amino acid PET into surgical planning allows
better delineation of the extent of resection beyond margins
visible with standard MRI. This is of considerable importance
whenever functional eloquent areas of brain are involved.
† For biopsy planning, amino acid PET is particularly helpful in
identifying malignant foci within non-contrast-enhancing
gliomas.
Value for Treatment Planning: Radiation
Beyond MRI-based morphologic gross tumor volume delinea-
tion, a biological tumor volume may be defined by radiotracer
uptake on amino acid PET that identifies tumor beyond the ex-
tent visible with standard MRI.47 In addition, the biologic and
metabolic information provided by PETmay identify subregions
of tumor at higher risk of recurrence, which can be included in
the radiation boost volume. The ability to better define tumor
extent and biology may be used to improve the therapeutic
ratio of radiation treatment. The current recommendations
focus on the role of PET for radiation planning of WHO grades
III/IV gliomas, as the role of PET imaging in irradiation of WHO
grade II gliomas is not well established.
Small, prospective studies systematically comparing contrast
MRI tumor volume (the “standard” radiation boost target) and
18F-FDG uptake abnormality generally demonstrate a smaller
region of 18F-FDG uptake contained within the MRI abnormality,
with only occasional extension outside of the MRI target.48,49 Al-
though small studies have demonstrated the feasibility of radia-
tion boost planning using 18F-FDG PET, its utility is limited by the
low contrast between tumor and normal cortex.48
Studies analyzing patterns of failure following conventional
chemoradiotherapy based on standard MRI-defined tumor vol-
umes suggest that amino acid PET–defined tumor volumes
may yield a more appropriate radiation target volume.50–52
In these small studies, a proportionate increase in marginal
or noncentral tumor recurrences were seen when regions of
11C-MET and 18F-FET abnormality were not adequately covered
by high-dose radiation. Prospective, single-arm studies evaluat-
ing the use of amino acid PET for radiation treatment planning
of recurrent WHO grades III/IV glioma suggest the feasibility of
this approach, and most studies suggest an improvement in
outcome compared with radiation planning based on conven-
tional MRI alone.53,54 However, the inclusion of amino acid
PET–based tumor volumes in standard-dose radiation therapy
and reirradiation protocols continue to demonstrate a predom-
inance of in-field tumor recurrences, highlighting the need for
more effective therapies.53–56
† Amino acid PET may improve the delineation of a biological
tumor volume beyond conventional MRI and identify aggres-
sive tumor subregions that may be targeted by radiation
therapy.
† While 18F-FDG PET is of limited utility in radiation treatment
planning of WHO grades III/IV gliomas, radiation planning
using amino acid PET appears feasible, with preliminary evi-
dence of potential benefit.
Follow-up: Treatment Response, Progression,
Pseudoprogression, and Radionecrosis
To date, standard, structural MRI is the most important diagnos-
tic tool for assessing treatment effects in patients with gliomas.4
The extent of contrast enhancement on MRI is usually consid-
ered an indicator of treatment response (eg, Macdonald criteria,
RANO criteria),5,57 although its reliability in distinguishing tumor
tissue from treatment effects, which can include blood–brain
barrier breakdown, is limited.58 For example, transient blood–
brain barrier alteration with contrast enhancement—such as
after radiotherapy with or without concomitant temozolomide—
can mimic tumor progression and is termed “pseudoprogres-
sion.”59,60 In addition, since the introduction of anti-angiogenic
agents such as bevacizumab, the phenomenon of pseudores-
ponse complicates the assessment of treatment response using
standard MRI alone.59,61
WHO grades III/IV glioma
Few 18F-FDG PET studies have measured the glucose metabolic
rate following either radiotherapy, chemotherapy, or both:
decrease of 18F-FDG uptake correlates with treatment
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response.62–64 18F-FDG PET has been found to be of only mod-
erate additional value to MRI for differentiation betweenmalig-
nant glioma recurrence and radionecrosis, especially due to low
specificity.65,66,67,68 However, there are several limitations:
most studies were retrospective, jointly assessed gliomas of
all WHO grades, used differing treatments, had varying assess-
ment strategies, and utilized varying 18F-FDG thresholds of
tumor to normal brain for image interpretation.
The feasibility and usefulness of amino acid PET such as
11C-MET, 18F-FET, or 18F-FDOPA PET for treatment assessment
after chemoradiotherapy, stereotactic brachytherapy, chemo-
therapy, and other experimental approaches have been dem-
onstrated in several studies, primarily in WHO grades III/IV
gliomas. Current amino acid PET data suggest that a reduction
of amino acid uptake and/or a decrease of the metabolically
active tumor volume is a sign of treatment response associated
with long-term outcome.69–73 Amino acid PET using 18F-FET
may facilitate the diagnosis of pseudoprogression in glioblasto-
ma patients within the first 12 weeks following completion of
chemoradiotherapy.74
Furthermore, several studies suggest that treatment re-
sponse and outcome in bevacizumab therapy can be assessed
by amino acid PET using 18F-FET and 18F-FDOPA better than by
MRI.75–78
Amino acid PET is useful for the differentiation between
treatment-related changes and true progression with high sen-
sitivity and specificity.37,79,80 A combination of static and dy-
namic 18F-FET PET parameters identified correctly progressive
or recurrent glioma with higher accuracy (93%) than conven-
tional MRI.81
WHO grade II glioma
In contrast to patients with WHO grades III/IV gliomas, the ex-
perience with amino acid PET for monitoring after treatment in
patients with WHO grade II gliomas is limited, with only a few
studies available in the literature.82,83 As these tumors are usu-
ally negative on 18FDG PET, the latter is not suitable for re-
sponse evaluation.
† Analysis of 18F-FDG uptake does not reliably distinguish be-
tween recurrence and radionecrosis.
† A decrease in amino acid uptake and/or volume is associated
with treatment response across gliomas ofWHO grades III/IV.
† Amino acid PET improves the assessment of pseudoprogres-
sion, radionecrosis, and pseudoresponse.
Prognostication
The prognostic value of 18F-FDG uptake in gliomas has been
suggested by several studies.84 –87 Additionally, pretreatment
18F-FDG PET has been reported to correlate with survival in pa-
tients with newly diagnosed glioblastoma88 or recurrent high-
grade gliomas receiving bevacizumab.89
The prognostic value of amino acid PET has been increasingly
explored.15,90–92 At diagnosis, dynamic 18F-FET PET identified
highly aggressive astrocytomas within the same WHO grade—
for instance,WHO grade II gliomas with decreasing time-activity
curves manifested earlier tumor progression, malignant trans-
formation, as well as shorter survival.91,93 Similarly dynamic
18F-FET PET identified anaplastic astrocytomas with a very
early decrease of time-activity curves—and consequently short
time-to-peak—as having a comparably poor outcome.15
To date, the association of glioma 18F-FET uptake with sur-
vival has remained controversial. Some groups have reported
a better outcome of patients with absent or only low tumoral
amino acid uptake.86,90,94 In contrast, a larger study of
18F-FET-negative glioma patients did not reveal an association
with improved outcome, as neither time to transformation,
which was proven upon histological evaluation, nor overall sur-
vival differed from that of FET-positive glioma patients.15
A prospective multicenter trial investigating the role of pre-
treatment 18F-FET PET in newly diagnosed glioblastoma found
biological tumor volume prior to chemoradiotherapy to be
highly prognostic for outcome.46 This is in accordance with re-
sults of previous studies investigating amino acid PET in malig-
nant glioma prior to therapy.69,95
† Uptake of 18F-FDG and amino acid tracer is associated with
outcome inWHO grades III/IV glioma both in a pretreatment
setting and following therapy.
† Biological tumor volume in amino acid PET is associated with
survival following therapy in glioblastoma.
† Dynamic analysis of 18F-FETuptake provides prognostic infor-
mation within all grades of glioma prior to treatment.
Current Limitations
While 18F-FDG is used at all PET sites, only a few centers offer
amino acid PET so far. However, due to the 18F labeling of FET
and FDOPA, the radiotracer can be delivered in the sameway as
18F-FDG, facilitating the availability of amino acid PET. Only for
11C-MET is an on-site cyclotron required. The major obstacle
for the widespread use of amino acid PET in glioma patients
is to date the limited reimbursement by health insurance
companies/institutions, despite the fact that current data
clearly favor amino acid over 18F-FDG PET.
Across all tracers, numerous studies differed in terms of
methodology, which limits comparability of data and might
eventually jeopardize acceptance in the clinical setting. Howev-
er, this guideline collected convincing support that PET imaging
is of additional value beyond MRI in glioma management.
Outlook Perspective
Future clinical studies should consider the use of amino acid
PET as an imaging modality for gliomas complementary to
MRI. Standardized technical guidelines for PET imaging proce-
dures and recommendations by the EANM/EANO/RANO group
will be published separately.
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response.62–64 18F-FDG PET has been found to be of only mod-
erate additional value to MRI for differentiation betweenmalig-
nant glioma recurrence and radionecrosis, especially due to low
specificity.65,66,67,68 However, there are several limitations:
most studies were retrospective, jointly assessed gliomas of
all WHO grades, used differing treatments, had varying assess-
ment strategies, and utilized varying 18F-FDG thresholds of
tumor to normal brain for image interpretation.
The feasibility and usefulness of amino acid PET such as
11C-MET, 18F-FET, or 18F-FDOPA PET for treatment assessment
after chemoradiotherapy, stereotactic brachytherapy, chemo-
therapy, and other experimental approaches have been dem-
onstrated in several studies, primarily in WHO grades III/IV
gliomas. Current amino acid PET data suggest that a reduction
of amino acid uptake and/or a decrease of the metabolically
active tumor volume is a sign of treatment response associated
with long-term outcome.69–73 Amino acid PET using 18F-FET
may facilitate the diagnosis of pseudoprogression in glioblasto-
ma patients within the first 12 weeks following completion of
chemoradiotherapy.74
Furthermore, several studies suggest that treatment re-
sponse and outcome in bevacizumab therapy can be assessed
by amino acid PET using 18F-FET and 18F-FDOPA better than by
MRI.75–78
Amino acid PET is useful for the differentiation between
treatment-related changes and true progression with high sen-
sitivity and specificity.37,79,80 A combination of static and dy-
namic 18F-FET PET parameters identified correctly progressive
or recurrent glioma with higher accuracy (93%) than conven-
tional MRI.81
WHO grade II glioma
In contrast to patients with WHO grades III/IV gliomas, the ex-
perience with amino acid PET for monitoring after treatment in
patients with WHO grade II gliomas is limited, with only a few
studies available in the literature.82,83 As these tumors are usu-
ally negative on 18FDG PET, the latter is not suitable for re-
sponse evaluation.
† Analysis of 18F-FDG uptake does not reliably distinguish be-
tween recurrence and radionecrosis.
† A decrease in amino acid uptake and/or volume is associated
with treatment response across gliomas ofWHO grades III/IV.
† Amino acid PET improves the assessment of pseudoprogres-
sion, radionecrosis, and pseudoresponse.
Prognostication
The prognostic value of 18F-FDG uptake in gliomas has been
suggested by several studies.84 –87 Additionally, pretreatment
18F-FDG PET has been reported to correlate with survival in pa-
tients with newly diagnosed glioblastoma88 or recurrent high-
grade gliomas receiving bevacizumab.89
The prognostic value of amino acid PET has been increasingly
explored.15,90–92 At diagnosis, dynamic 18F-FET PET identified
highly aggressive astrocytomas within the same WHO grade—
for instance,WHO grade II gliomas with decreasing time-activity
curves manifested earlier tumor progression, malignant trans-
formation, as well as shorter survival.91,93 Similarly dynamic
18F-FET PET identified anaplastic astrocytomas with a very
early decrease of time-activity curves—and consequently short
time-to-peak—as having a comparably poor outcome.15
To date, the association of glioma 18F-FET uptake with sur-
vival has remained controversial. Some groups have reported
a better outcome of patients with absent or only low tumoral
amino acid uptake.86,90,94 In contrast, a larger study of
18F-FET-negative glioma patients did not reveal an association
with improved outcome, as neither time to transformation,
which was proven upon histological evaluation, nor overall sur-
vival differed from that of FET-positive glioma patients.15
A prospective multicenter trial investigating the role of pre-
treatment 18F-FET PET in newly diagnosed glioblastoma found
biological tumor volume prior to chemoradiotherapy to be
highly prognostic for outcome.46 This is in accordance with re-
sults of previous studies investigating amino acid PET in malig-
nant glioma prior to therapy.69,95
† Uptake of 18F-FDG and amino acid tracer is associated with
outcome inWHO grades III/IV glioma both in a pretreatment
setting and following therapy.
† Biological tumor volume in amino acid PET is associated with
survival following therapy in glioblastoma.
† Dynamic analysis of 18F-FETuptake provides prognostic infor-
mation within all grades of glioma prior to treatment.
Current Limitations
While 18F-FDG is used at all PET sites, only a few centers offer
amino acid PET so far. However, due to the 18F labeling of FET
and FDOPA, the radiotracer can be delivered in the sameway as
18F-FDG, facilitating the availability of amino acid PET. Only for
11C-MET is an on-site cyclotron required. The major obstacle
for the widespread use of amino acid PET in glioma patients
is to date the limited reimbursement by health insurance
companies/institutions, despite the fact that current data
clearly favor amino acid over 18F-FDG PET.
Across all tracers, numerous studies differed in terms of
methodology, which limits comparability of data and might
eventually jeopardize acceptance in the clinical setting. Howev-
er, this guideline collected convincing support that PET imaging
is of additional value beyond MRI in glioma management.
Outlook Perspective
Future clinical studies should consider the use of amino acid
PET as an imaging modality for gliomas complementary to
MRI. Standardized technical guidelines for PET imaging proce-
dures and recommendations by the EANM/EANO/RANO group
will be published separately.
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